NewAmsterdam Pharma Co N.V.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — |
| Selling, general & administrative | $106.4M | $70.4M | $37.6M | $19.5M | $6.0M |
| Research and development | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M |
| Operating expenses | $248.2M | $221.9M | $197.1M | $106.3M | $35.0M |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M | -$35.0M |
| Interest expense | — | — | — | $287,000 | $411,000 |
| Pretax income | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M |
| Income tax expense | — | -$1,000 | $27,000 | — | — |
| Net income | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M |
| Balance Sheet | |||||
| Cash and equivalents | $490.0M | $771.7M | $340.4M | — | — |
| Current assets | $675.7M | $863.4M | $346.8M | $478.0M | — |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M | — |
| Current liabilities | $85.8M | $106.9M | $49.9M | $36.1M | — |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M | — |
| Stockholders' equity | $683.4M | $757.5M | $288.4M | $430.1M | -$113.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$147.8M | -$158.6M | -$141.2M | $10.7M | -$29.5M |
| Depreciation and amortization | $220,000 | $113,000 | $49,000 | $9,000 | $5,000 |
| Stock-based compensation | $59.4M | $33.6M | $24.6M | $4.1M | $1.2M |
| Capital expenditure | $246,000 | $672,000 | $24,000 | $221,000 | $24,000 |
| Free cash flow | -$148.0M | -$159.2M | -$141.2M | $10.4M | -$29.5M |
Shares outstanding 116.9M · Free float 56.9%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.